Company Filing History:
Years Active: 2017-2022
Title: Christina Lorenz: Innovator in Vaccine Development
Introduction
Christina Lorenz is a prominent inventor based in Basel, Switzerland. She has made significant contributions to the field of vaccine development, particularly in the area of combining vaccination with inhibition of MHC class I restricted antigen presentation. With a total of 2 patents, her work is paving the way for advancements in immunotherapy.
Latest Patents
One of Christina's latest patents focuses on a vaccine/inhibitor combination that includes at least one antigen as a vaccine and at least one inhibitor of the major histocompatibility complex (MHC) class I restricted antigen presentation. This innovative approach not only enhances the immune response against tumor cells but also targets infected cells that have lost the capability of MHC class I restricted antigen presentation. The invention also encompasses a method for vaccinating mammals using this combination, as well as a kit of parts for the administration of the vaccine/inhibitor combination.
Career Highlights
Christina Lorenz is currently associated with CureVac AG, a company known for its pioneering work in mRNA technology and vaccine development. Her role at CureVac AG allows her to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Some of Christina's notable coworkers include Mariola Fotin-Mleczek and Karl-Josef Kallen. Their collaborative efforts are instrumental in advancing the research and development of innovative vaccine solutions.
Conclusion
Christina Lorenz is a key figure in the field of vaccine innovation, with her patents reflecting a commitment to improving immune responses against various diseases. Her work at CureVac AG and collaborations with esteemed colleagues further enhance her impact on the future of immunotherapy.